OPEN CALL FOR DRUG DISCOVERY PARTNERSHIPS IN DUBAI
Secondcell Bio uses biotechnology invented at Rockefeller University to implement numerous drug discovery programs in the United Arab Emirates.
— Dr. Kambiz Shekdar, inventor
Similar to the scale-up of automated DNA sequencing methods that ushered in the era of the Human Genome Project, Secondcell Bio uses robotic, scalable technology invented at Rockefeller University for scale-up. of its technology in a factory-like public-private partnership in the United Arab Emirates. to discover and develop new pharmaceutical drugs.
“Our transformative cell biotechnology uses Molecular Lightbulbs™ to remove bottlenecks in cell-based drug discovery. The public-private partnership in the UAE allows us to fully harness the potential of our technology for science and human health,” says Dr. Shekdar, PhD, inventor and founder of Secondcell Bio.
Secondcell Bio is a private biotechnology company with access to the core technology and know-how developed by its founder. The technology was developed with over $100 million in funding from private sources and with no funding from the NIH or other US government, making it a rare and mature cutting-edge biotechnology, unencumbered and available for the exporting and franchising globally.
Currently, Secondcell Bio is looking to build a strong team of scientific and medical advisors around the world. In particular, researchers and research institutions from the UAE and the region are encouraged to reach out.
Priority areas include refractory diseases for which newly identified drug targets have been reported, systems biology applications including diseases mediated by large gene families and heteromultimeric targets, and disease variants representing populations under-represented, rare and orphan indications.
The partnership is poised to open up new territory in drug discovery and development, including for personalized medicine, leveraging an individual’s human genome data to develop new drugs. This is made possible because Secondcell Bio’s technology enables the implementation of personalized drug discovery and development that is both rapid and cost effective. Researchers who have identified potential drug targets or SNPs for one or more individuals are strongly encouraged to get in touch to explore personalized drug discovery partnerships.
ABOUT SECONDECELL BIO
Secondcell Bio is setting up a public-private partnership in the United Arab Emirates to develop its demonstrated and largely automated biotechnology platform originating from Rockefeller University. Called, Chromovert® The technology, method, and a variety of example results for the platform technology can be found here: https://link.springer.com/article/10.1007/s10529-021-03101-5.
J. Dianne Dotson
write to us here